title: Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
abstract: OBJECTIVE
  Studies on the expression of somatostatin receptor (SSTR) subtypes in pancreatic neuroendocrine tumors (PNETs) are rare. The aim of this study was to determine the expression of the SSTR subtypes via immunohistochemistry analyses and assess the correlation between SSTR subtype expression and prognosis.
  
  
  METHODS
  We examined 199 patients with PNET who underwent surgical resection between January 1995 and December 2010 at the Asan Medical Center. For all cases, medical records, including demographic data, clinical symptoms, radiological findings, postoperative treatment outcomes, and expression of SSTR subtypes, were carefully reviewed.
  
  
  RESULTS
  In total, 162 (81.4%) PNETs expressed more than 1 SSTR subtype. Functioning PNET expressed significantly more SSTR subtypes, compared to nonfunctioning PNET. The SSTR2(+) and SSTR5(+) groups had better prognosis than the SSTR2(-) (P = 0.009) and SSTR5(-) groups (P = 0.03), respectively. In the grade 2 PNET of 2010 World Health Organization classification, the SSTR(+) group had better prognosis than SSTR(-) group.
  
  
  CONCLUSIONS
  The expression of SSTR 2 and 5 were related with good prognosis of PNET. In World Health Organization grade 2 PNET, the SSTR(+) group had better prognosis than SSTR(-) group. The SSTR expression(+) by immunohistochemistry might be related with good prognosis of the patients with surgically resected PNET.
authors.affiliation: From the *Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, †Department of Pathology, and ‡Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, South Korea.
authors.forename: Ki Byung
authors.initials: KB
authors.lastname: Song
authors.forename: Song Cheol
authors.initials: SC
authors.lastname: Kim
authors.forename: Ji Hun
authors.initials: JH
authors.lastname: Kim
authors.forename: Dong-Wan
authors.initials: DW
authors.lastname: Seo
authors.forename: Seung-Mo
authors.initials: SM
authors.lastname: Hong
authors.forename: Kwang-Min
authors.initials: KM
authors.lastname: Park
authors.forename: Dae Wook
authors.initials: DW
authors.lastname: Hwang
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Young-Joo
authors.initials: YJ
authors.lastname: Lee
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000378:metabolism* / Q000601:surgery; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000601:surgery; D011379:Prognosis; D017481:Receptors, Somatostatin / Q000378:metabolism*; D012189:Retrospective Studies
chemical_list: D017481:Receptors, Somatostatin; C574734:SSTR2 protein, human; C103631:somatostatin receptor 3; C098681:somatostatin receptor subtype-4; C101130:somatostatin receptor type 1; C094573:somatostatin receptor 5